NCT05559541View on ClinicalTrials.gov

Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions

Solid Tumor, Adult

Interventions

DRUG

AK119

AK119 is an anti-CD73 monoclonal antibody.

DRUG

AK104

AK104 is an anti-PD-1 and CTLA-4 bispecific antibody.

Trial Locations (1)

300060

Tianjin Medical University Cancer Insitute & Hospital, Tianjin

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Akeso

INDUSTRY